|
Daily Medical Update
Acute Kidney Injury
Thursday, May 14, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Medicine (2026) - Meta-Analysis
Key Findings
- Early RRT reduced 28-day mortality versus later RRT (risk ratio 0.81; 95% confidence interval 0.72-0.91), with pooled mortality 44.7% vs 47.8%.
- Early RRT did not improve renal recovery or RRT dependence versus later initiation, despite the mortality reduction.
📋 Practice Implication: For critically ill patients with AKI who are approaching dialysis thresholds, earlier RRT initiation merits consideration when the near-term priority is survival rather than renal recovery.
|
JAMA (2026) - Meta-Analysis
Key Findings
- SGLT2 inhibitors lowered acute kidney injury rates in patients with diabetes (14 vs 18 per 1000 patient-years; hazard ratio 0.77; 95% confidence interval 0.69-0.87) and without diabetes (13 vs 18 per 1000; hazard ratio 0.72; 95% confidence interval 0.56-0.92).
- Kidney disease progression was reduced with SGLT2 inhibitors in diabetes (hazard ratio 0.65) and without diabetes (hazard ratio 0.74), with larger absolute kidney benefits at UACR 200 mg/g or greater.
📋 Practice Implication: In CKD populations at risk for AKI, SGLT2 inhibitors appear to offer kidney protection regardless of diabetes status, supporting use based on renal risk rather than diabetes alone.
|
Clinical nephrology (2026) - Meta-Analysis
Key Findings
- SGLT2 inhibitors reduced progressive kidney disease in patients with diabetes (odds ratio 0.64; 95% confidence interval 0.58-0.71) and without diabetes (odds ratio 0.69; 95% confidence interval 0.57-0.83), with no effect modification by diabetes status.
- Diabetic ketoacidosis risk increased in diabetic patients receiving SGLT2 inhibitors (odds ratio 2.18; 95% confidence interval 1.61-2.97), while renal adverse events did not increase versus placebo.
📋 Practice Implication: When choosing SGLT2 therapy for renal protection, clinicians can expect benefit in diabetic and non-diabetic CKD while still needing drug-specific counseling and monitoring for ketoacidosis in diabetic patients.
|
Scientific reports (2026) - Meta-Analysis
Key Findings
- Elevated UACR increased the odds of incident AKI (odds ratio 1.39; 95% confidence interval 1.08-1.79) and AKI progression (odds ratio 3.76; 95% confidence interval 2.59-5.45).
- UACR improved AKI prediction with area under the curve 0.74, sensitivity 0.71, and specificity 0.67.
📋 Practice Implication: Baseline UACR can be used as a low-cost triage signal to identify hospitalized patients who may need closer creatinine and urine output surveillance for AKI.
|
BMC nephrology (2025) - Meta-Analysis
Key Findings
- Nicorandil reduced contrast-induced nephropathy versus control during coronary procedures (risk ratio 0.37; 95% confidence interval 0.27-0.49; p < 0.001).
- Nicorandil reduced post-procedure creatinine rise at 24, 48, and 72 hours, but did not improve eGFR or reduce major adverse events versus control.
📋 Practice Implication: For coronary intervention patients with substantial contrast nephropathy risk, nicorandil may be a useful adjunct where local practice and availability support its use.
|
|
💡
Summary
Recent AKI evidence emphasizes earlier intervention, better prevention around high-risk exposures, and practical risk stratification. Meta-analyses found lower 28-day mortality with earlier renal replacement therapy in critical illness, lower AKI rates with SGLT2 inhibitors across diabetes and albuminuria strata, and promising biomarker and peri-procedural strategies that may help identify or reduce AKI in selected settings.
|
|